MedTrace Logo

Retrospective Analysis of Real World Use of Ceftazidime-avibactam in the Management of Gram Negative Infections

NCT04628572 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 189

Last updated 2024-08-14

Study results available
· View outcomes & findings →

Summary

The main objective of this non-interventional (retrospective) study is to describe the general treatment patterns, effectiveness, and safety of ceftazidime-avibactam in real-world settings in India. Eligible patients would be adults who have been treated with ≥ 48 hours of ceftazidime-avibactam in routine practice from 01 June 2019 to 01 April 2020. Data of 500 patients will be collected through the abstraction of hospital medical records (electronic) if available or through the individual patient medical record in case electronic records are not available.

Conditions

  • Gram Negative Infections

Interventions

DRUG

Ceftazidime-avibactam

Non-Interventional Study

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-29
Primary Completion
2022-03-11
Completion
2022-03-11
FDA Drug
Yes

Countries

  • India

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04628572 on ClinicalTrials.gov